Uses
AL 8810 isopropyl ester is an 11β-fluoro analog of prostaglandin F2α which acts as a potent and selective antagonist at the FP receptor. AL 8810 isopropyl ester is a lipid soluble, esterified prodrug form of AL 8810 isopropyl ester analogous to the commonly used therapeutic intraocular prostaglandin compounds such as Latanoprost and Travoprost. The pharmacology of AL 8810 isopropyl ester has not been published.[Cayman Chemical]
Biological Activity
ec50: 430 nmal 8810 is a a fp receptor antagonist.prostaglandin f receptor (fp), a receptor belonging to the prostaglandin (pg) group of receptors, binds to and mediates the biological actions of prostaglandin f2α (pgf2α).
in vitro
previous study found that al-8810 had weak agonist potency in a7r5 cells and 3t3 fibroblasts. al-8810 exhibited properties of an apparent competitive antagonist, which was demonstrated by producing parallel dextral shifts of the agonist concentration-response curves and no significant suppression of the maximal agonist-induced response. in addition, al-8810 could dose-dependently antagonize the response to 100 nm fluprostenol in a7r5 cells, but however, al-8810 could not significantly inhibit functional responses of dp, tp, ep(2), ep(4), receptor subtypes even at 10 μm concentration [1].
in vivo
in a previous study, the effect of acute intraperitoneal post-treatment with al-8810 was studied in fp receptor knockout (fp-/-) mice after controlled cortical impact (cci). results showed that post-treatment with al-8810 had no significant effect on cortical lesions, suggesting the irreversible effect of primary cci injury, but significantly reduced hippocampal swelling. in addition, al-8810 treatment at a dose of 10 mg/kg could significantly improve nds after cci, and in the al-8810 group, cci-induced decrease in grip strength was three-fold less [2].
References
[1] b. w. griffen, p. klimko, j. y. crider, et al. al-8810: a novel prostaglandin f2α analog with selective antagonist effects at the prostaglandin f2α (fp) receptor. journal of pharmacology and experimental therapeutics 290(3), 1278-1284 (1999).
[2] glushakov av, robbins sw, bracy cl, narumiya s, doré s. prostaglandin f2α fp receptor antagonist improves outcomes after experimental traumatic brain injury. j neuroinflammation. 2013 oct 30;10:132. doi: 10.1186/1742-2094-10-132.
